Biopharmaceutical firm XBiotech has partnered with non-profit BioBridge Global to develop a Covid-19 therapy using natural antibodies from convalescent plasma of recovered patients.

The project is part of the US Food and Drug Administration (FDA)’s investigational programme for blood centre across the country to collect and distribute convalescent plasma related to the novel coronavirus infection.

Under the partnership, BioBridge Global subsidiary South Texas Blood & Tissue Center (STBTC) will collect the plasma from donors for the potential treatment of infected patients.

STBTC will provide blood samples to XBiotech for the development of a True Human antibody therapy candidate for the infection.

XBiotech chief scientific officer Dr Sushma Shivaswamy said: “XBiotech is working to contribute solutions to reducing the impact of the Covid-19 pandemic. Our unique human antibody technology at XBiotech has been developed specifically to address these kinds of issues.”

In addition, XBiotech developed a clinical test used by BioBridge Global unit QualTex Laboratories to detect natural antibodies in human blood that act against the novel coronavirus.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

QualTex can use the test to identify blood containing naturally neutralising antibodies in recovered individuals.